ESMO Voices from China | Professor Qingqing Cai: Rocbrutinib Plus R-CHOP as First-Line Treatment for Non-GCB DLBCL—Deep Responses and a Favorable Long-Term Safety Profile with No Atrial Fibrillation or Major Bleeding

ESMO Voices from China | Professor Qingqing Cai: Rocbrutinib Plus R-CHOP as First-Line Treatment for Non-GCB DLBCL—Deep Responses and a Favorable Long-Term Safety Profile with No Atrial Fibrillation or Major Bleeding

Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) is characterized by substantial molecular heterogeneity. Compared with the GCB subtype, it generally responds less favorably to conventional immunochemotherapy and is associated with poorer outcomes, making it a challenging subtype in clinical practice. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Qingqing Cai's team from Sun Yat-sen University Cancer Center presented data from a multicenter Phase Ib study (1457O) evaluating the safety and preliminary efficacy of rocbrutinib, a novel fourth-generation Bruton tyrosine kinase (BTK) inhibitor, in combination with R-CHOP as first-line treatment for B-cell lymphoma. The study demonstrated an objective response rate (ORR) of 100% and a complete response (CR) rate of 86.7% among patients with newly diagnosed non-GCB DLBCL, with no cases of atrial fibrillation or severe bleeding observed. In this article, we invited Professor Qingqing Cai to provide an in-depth interpretation of the translational value and future research directions of this regimen, covering its pharmacological mechanisms, minimal residual disease (MRD)-guided strategies, and the future clinical development landscape.
2026 CTIC Congress | Professor Mohamad Mohty: Ending Four Decades of Stagnation in cGVHD—From Decoding Pathological Mechanisms to a New Era of Cell Therapy

2026 CTIC Congress | Professor Mohamad Mohty: Ending Four Decades of Stagnation in cGVHD—From Decoding Pathological Mechanisms to a New Era of Cell Therapy

Qiantang Forum, Shaping the Future Through Innovation. From November 6 to 8, 2026, the 2026 Cellular Therapy and Immunotherapy Conference (CTIC 2026) was grandly held in Hangzhou. Taking a global perspective, the congress brought together leading experts and scholars from China and abroad to explore cutting-edge developments in cellular therapy, gene therapy, AI-enabled hematology, and translational research, addressing clinical challenges and charting a path toward high-quality development in the field. During the congress, Oncology Frontier – Hematology Frontier invited Professor Mohamad Mohty of Sorbonne University, France, who also served as the congress chair, to share his latest research findings and academic insights into mechanistic breakthroughs in chronic graft-versus-host disease (cGVHD) over the past decade, the immunological balance between GVHD and GVL, and the future role of cell therapy. The key points are presented below.
2026 SIU Congress | Professor Jeremy Teoh: Bringing Asian Urology to the Global Stage Through High-Quality Research and International Collaboration

2026 SIU Congress | Professor Jeremy Teoh: Bringing Asian Urology to the Global Stage Through High-Quality Research and International Collaboration

The 46th Annual Congress of the Société Internationale d'Urologie (SIU) was held in Florence, Italy, from November 11 to 14, 2026. On this occasion, Oncology Frontier – UroStream invited Professor Jeremy Yuen Chun Teoh of the Faculty of Medicine, The Chinese University of Hong Kong, Chair of the Organizing Committee of this year's congress, to share his insights on the overall congress program, the development of Asian urology and its pathway toward greater international academic collaboration, as well as his motivation and vision for running for the position of SIU General Secretary-elect.
Professor Darren Poon: Optimizing Perioperative Bladder Cancer Care and Advancing Collaboration in Asia

Professor Darren Poon: Optimizing Perioperative Bladder Cancer Care and Advancing Collaboration in Asia

At the European Society for Medical Oncology (ESMO) Congress 2026, perioperative treatment for bladder cancer remained a key focus. How systemic therapies can be integrated with surgery, while balancing efficacy, cumulative toxicity and treatment burden, is an important clinical question. In this interview with Oncology Outlook · Urology Times, Professor Darren Poon discusses the implications of VOLGA, the potential impact on practice in Hong Kong, China, and his expectations for the inaugural ESMO Genitourinary Cancers Asia congress in 2027.
ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Total neoadjuvant therapy (TNT) for locally advanced rectal cancer has become a major focus of research in recent years. A central unresolved question has been whether improvements in pathological complete response (pCR) rates can translate into meaningful survival benefits. At the same time, developing individualized neoadjuvant strategies for patients with different molecular subtypes based on biomarkers remains an urgent clinical priority.
ESMO Oncology Update | Neoadjuvant Enfortumab Vedotin Plus Perioperative Durvalumab Significantly Improves EFS and OS in Patients with MIBC

ESMO Oncology Update | Neoadjuvant Enfortumab Vedotin Plus Perioperative Durvalumab Significantly Improves EFS and OS in Patients with MIBC

The EV-303 and EV-304 studies have expanded the treatment landscape for muscle-invasive bladder cancer (MIBC) by incorporating perioperative enfortumab vedotin plus pembrolizumab into treatment strategies. At the 2026 European Society for Medical Oncology (ESMO) Congress, the phase III VOLGA study reported positive results. In patients with MIBC who were cisplatin-ineligible, neoadjuvant enfortumab vedotin plus perioperative durvalumab, with or without tremelimumab, significantly improved the primary endpoint of event-free survival (EFS) compared with radical cystectomy (RC) alone: median EFS was not reached versus 12.1 months (HR 0.51; 95% CI, 0.38–0.67; P<0.0001).
ESMO Voices from China | Professor Xue Meng: 100% MPR Rate in the First Stage — Exploring a Chemotherapy-Free Neoadjuvant Approach to NSCLC with Sequential SBRT and Iparomlimab/Toripalimab

ESMO Voices from China | Professor Xue Meng: 100% MPR Rate in the First Stage — Exploring a Chemotherapy-Free Neoadjuvant Approach to NSCLC with Sequential SBRT and Iparomlimab/Toripalimab

Platinum-based chemotherapy combined with immunotherapy has become an important perioperative treatment option for resectable non-small cell lung cancer (NSCLC). However, selecting an appropriate regimen remains challenging for patients who are unsuitable for platinum-based chemotherapy. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Xue Meng's team presented a phase II exploratory study investigating stereotactic body radiotherapy (SBRT) followed sequentially by iparomlimab/toviralimab (hereinafter referred to as the “Ipa-Tori combination antibody”), with continued immunotherapy after surgery. In the first-stage results, all nine patients achieved a major pathological response (MPR), representing an MPR rate of 100%. The pathological complete response (pCR) rate was 55.6% (5/9), and all patients underwent R0 resection. These findings provide preliminary support for further investigation, although validation in a larger patient population is needed. Oncology Frontier interviewed Professor Xue Meng about the study design, patient selection, and directions for further validation.